|
|
Article: Neurocrine Reports Positive Results for Adult Chronic Insomnia Patients After Middle of the Night Dosing With Indiplon; Treatment With Indiplon Immediate Release Results in Rapid Return to Sleep and Improved Sleep Quality With More Next Day Alertness as Compared to Placebo.
- Article from:
- PR Newswire
- Article date:
- December 9, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Neurocrine Biosciences, Inc. today announced positive preliminary results from the Company's Phase II/III clinical trial for the immediate release formulation of indiplon, achieving highly statistically significant results in patients with chronic insomnia characterized by waking up in the middle of the night (MOTN). Results show that patients who woke up in the middle of the night and had difficulty in falling back to sleep, and took indiplon, were able to return to sleep rapidly with fewer awakenings and a better quality of sleep. Additionally, there was no evidence of next morning residual effects and patients taking indiplon demonstrated more next day alertness than ...
Related newspaper, magazine, and journal articles:
|
|
Article: Neurocrine Biosciences Announces Resubmission ...
PR Newswire;
February 7, 2005 ;
700+ words
...Neurocrine Biosciences announced today that it completed ... the resubmission of its indiplon immediate release and modified release New Drug Applications ... Lyons, President & CEO of Neurocrine Biosciences. "We will take advantage of the ...
|
|